SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?


To: zeta1961 who wrote (707)3/8/2005 10:47:22 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 1840
 
From PR:

"The Phase III study is designed to measure differences in overall survival, time to symptom progression and time to tumor progression of BAY 43- 9006 versus placebo in patients with advanced HCC. The trial will also evaluate the safety and pharmacokinetics of BAY 43-9006."